Recent

% | $
Quotes you view appear here for quick access.

GlaxoSmithKline plc Message Board

  • stemcellstoday stemcellstoday Feb 10, 2011 8:05 PM Flag

    Revascor - THE FIRST HUNDRED BILLION DOLLAR DRUG

    How much would you pay to add 10 years to your heart?

    20 million patients * $10,000 = $200 BILLION

    This is a CONSERVATIVE estimate, IMO. Fresh supplies of Revascor will soon be on hand at every hospital in the world. Initial adopters will be paying much more than $10K per shot. And there will be more than 1 million new patients every year!

    In the United States alone, congestive heart failure has an annual incidence of 670,000 patients, a prevalence of 6.2 million patients, and causes over 1.1. million hospitalizations and 300,000 deaths per year. Heart failure affects around 10 million in Europe and as many as 20 million worldwide.

    Revascor (allogenic mesenchymal cells) PII results:
    - Reduced SEVERE adverse cardiac events from 93.3% to 44.4%.
    - Reduced MAJOR adverse cardiac events (cardiac death, heart attack, or coronary revascularization procedures) from 40% to 6.7%
    - Reduced DEATH from cardiac causes from 13.3% to 0%

    Three-tiered approach to value creation
    1. Near-term revenues
    - approved patient-specific products for elite athletes and high-net worth individuals
    2. Mid-term value drivers underpinning capital growth
    - “off the shelf” products for major unmet medical needs
    3. Long-term sustainability
    - R&D product pipeline

    Our first-rate clinical results, together with completion of this strategic alliance, underscore Mesoblast's position as the world's leading stem cell and regnerative medicine company. Mesoblast will now have a market capitalization of approximately $1.5 billion, $280 million cash on hand...

    This strategic alliance has the potential to transform Cephalon into one of the world's leading biopharmaceutical companies in the cardiovascular space. With Cephalon as a partner, we are uniquely equipped to develop additional therapeutics for a range of neurological conditions.

    Will CEPH be able to fend off a hostile takeover? Their current market cap is only 4 billion and with their other products alone, they are still vastly undervalued at this price.

    http://messages.finance.yahoo.com/mb/CEPH

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
GSK
46.66-0.69(-1.46%)Mar 26 4:01 PMEDT